Chronic disseminated candidiasis in patients with acute leukemia: Emphasis on diagnostic definition and treatment

Leukemia Research

Volumn 29, Issue 5, 2005, Pages 493-501

  Masood, Aisha ^a   Sallah, Sabah ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b Novonordisk   (Denmark)

Author keywords

Chronic candidiasis; Disseminated; Hepatosplenic

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; INTERLEUKIN 10 ANTIBODY; ITRACONAZOLE; KETOCONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ACUTE LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CANDIDIASIS; CHEMOTHERAPY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; HUMAN; IMAGING; LABORATORY TEST; LIVER BIOPSY; LIVER DISEASE; MEDICAL LITERATURE; MEDLINE; MORBIDITY; MORTALITY; MYCOSIS; NEPHROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; PRIORITY JOURNAL; PUBLICATION; SAFETY; TOXICITY;

EID: 14744280453     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.10.003     Document Type: Article

References (98)

1. M. Thaler, B. Pastakia, T.H. Shawker, T. O'Leary, and P.A. Pizzo Hepatic candidiasis in cancer patients, the evolving picture of syndrome Ann Intern Med 108 1988 88 100
2. E. Haron, R. Feld, P. Tuffnell, B. Patterson, R. Hasselback, and A. Matlow Hepatic candidiasis, an increasing problem in immunocompromised patients Am J Med 83 1987 17 26
3. G.H. Talbot, M. Provencher, and P.A. Cassileth Persistent fever after recovery from granulocytopenia in acute leukemia Arch Intern Med 148 1988 129 135
4. J.H. Lewis, H.R. Patel, and H.J. Zimmerman The spectrum of hepatic candidiasis Hepatology 2 1982 479 487
5. G.P. Bodey, D. De Jongh, A. Isassi, and E.J. Freireich Hypersplenism due to disseminated candidiasis in a patient with acute leukemia Cancer 26 1969 417 420
6. G.P. Bodey Fungal infections complicating acute leukemia J Chronic Dis 19 1966 667 687
7. R.C. Semelka, J.P. Shoenut, H.M. Greenberg, and E.J. Bow Detection of acute and treated lesions of hepatosplenic candidiasis, comparison of dynamic contrast-enhanced CT and MR imaging J Magn Reson Imaging 2 1992 341 345
8. S. Sallah, R.C. Semelka, N.L. Kelekis, S. Worawattanakul, and W. Sallah Diagnosis and monitoring response to treatment of hepatosplenic candidiasis in patients with acute leukemia using magnetic resonance imaging Acta Haematol 100 1998 77 81
9. N. Grois, G. Mostbeck, R. Scherrer, A. Chatt, I. Schwarzinger, and M. Muhm Hepatic and splenic abscesses, a common complication of intensive chemotherapy for acute myeloid leukemia Ann Hematol 63 1991 33 38
10. V.J. Anttila, E. Elonen, S. Nordling, A. Sivonen, T. Ruutu, and P. Ruutu Hepatosplenic candidiasis in patients with acute leukemia, incidence and prognostic implications Clin Infect Dis 24 1997 375 380
11. S. Sallah, R.C. Semelka, R. Wehbie, W. Sallah, N.P. Nguyen, and P. Vos Hepatosplenic candidiasis in patients with acute leukemia Br J Haematol 106 1999 697 701
12. F. Rossetti, D.L. Brawner, R. Bowden, W.G. Meyer, H.G. Schoch, and L. Fisher Fungal liver infections in marrow transplant recipients, prevalence at autopsy, predisposing factors and clinical features Clin Infect Dis 20 1995 801 811
13. J.W. Bjerke, J.D. Meyers, and R.A. Bowden Hepatosplenic candidiasis, a contraindication to marrow transplantation Blood 84 1994 2811 2814
14. V.J. Fraser, M. Jones, J. Dunkel, S. Strofer, G. Medoff, and W.C. Dunagan Candidemia in a tertiary care hospital, epidemiology, risk factors and predictors of mortality Clin Infect Dis 15 1992 414 421
15. S. Sallah Hepatosplenic candidiasis in patients with acute leukemia, increasingly encountered complication Anticancer Res 19 1999 757 760
16. A. Chubachi, I. Miura, A. Ohshima, T. Nishinari, T. Nimura, and H. Niitsu Risk factors for hepatosplenic abscesses in patients with acute leukemia receiving empiric azole treatment Am J Med Sci 308 1994 309 312
17. K.A. Marr, K. Seidel, T.C. White, and R.A. Bowden Candidemia in allogeneic blood and marrow transplant recipients, evolution of risk factors after the adoption of prophylactic fluconazole J Infect Dis 181 2000 309 316
18. V. Krcmery, E. Oracovaa, S. Spanik, M. Mrazova-Studena, J. Trupl, and A. Kunova Nosocomial breakthrough fungemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy, analysis of etiology, risk factors and outcome J Antimicrob Chemother 41 1998 373 380
19. P. Martino, C. Girmenia, M. Venditti, A. Micozzi, S. Santilli, and V.L. Burgio Candida colonization and systemic infection in neutropenic patients, a retrospective study Cancer 64 1989 2030 2034
20. H.F. Guiot, W.E. Fibbe, and J.W. van Wout Risk factors for fungal infections in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis Clin Infect Dis 18 1994 525 532
21. S. Sallah, J.Y. Wan, N.P. Nguyen, P. Vos, and A. Sigounas Analysis of factors related to the occurrence of chronic disseminated candidiasis in patients with acute leukemia in a non-bone marrow setting: a follow-up study Cancer 92 2001 1349 1353
22. Y. Kanda, R. Yamamoto, A. Chizuka, T. Hamaki, M. Suguro, and C. Arai Prophylactic action of oral fluconazole against fungal infection in neutropenic patients: a meta-analysis of 16 randomized, controlled trials Cancer 89 2000 1611 1625
23. E. Roilides, A. Anastasiou-Katsiardani, A. Dimitriadou-Georgiadou, I. Kadiltsoglou, S. Tsaparidou, and C. Panteliadis Suppressive effects of interleukin-10 on human mononuclear phagocyte function against Candida albicans and Staphylococcus aureus J Infect Dis 178 1998 1734 1742
24. E. Roilides, T. Sein, R. Schaufele, S.J. Chanock, and T.J. Walsh Increased serum concentrations of interleukin-10 in patients with hepatosplenic candidiasis J Infect Dis 178 1998 589 592
25. M.G. Netea, L.J. van Tits, J.H. Curfs, F. Amiot, J.F. Meis, and J.W. van der Meer Increased susceptibility of TNF-alpha lymphotoxin-alpha knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida J Immunol 163 1999 1498 1505
26. M. von Eiff, A. Fahrenkamp, N. Roos, W. Fegeler, and J. van de Leo Hepatosplenic candidiasis is a late manifestation of cancer septicemia Mycoses 33 1990 283 290
27. A. Verdeguer, J.M. Femandez, C. Esquembre, J. Ferris, J.G. Ruiz, and V. Castel Hepatosplenic candidiasis in children with acute leukemia Cancer 65 1990 874 877
28. V.J. Anttila, P. Ruutu, S. Bondestam, S.E. Jansson, S. Nordling, and M. Farkkila Hepatosplenic yeast infection in patients with acute leukemia, a diagnostic problem Clin Infect Dis 18 1994 979 981
29. T.L. Johnson, J.L. Barnett, H.D. Appelman, and T. Nostrant Candida hepatitis, histopathologic diagnosis Am J Surg Pathol 12 1988 716 720
30. D. D'Antonio, G. Fioritoni, A. Iacone, S. Betti, P. Fazii, and M. Dell'Isola Hepatosplenic infection caused by Candida parapsilosis in patients with acute leukemia Mycoses 35 1992 311 313
31. E.H. Phillips, B.J. Carroll, M. Chandra, L.A. Sullivan, P.J. Ruane, and R.W. Decker Laparoscopic-guided biopsy for diagnosis of hepatic candidiasis J Laparoendosc Surg 2 1992 33 38
32. V.J. Anttila, M. Farkkila, S.E. Jansson, M. Taavitsainen, T.S. Kaukoranta, and S. Nordling Diagnostic laparoscopy in patients with acute leukemia and suspected hepatic candidiasis Eur J Clin Microbiol Infect Dis 16 1997 637 643
33. N.L. Kelekis, R.C. Semelka, H.J. Jeon, S. Sallah, T.L. Shea, and J.T. Woosley Dark ring sign finding in patients with fungal liver lesions and transfusional hemosiderosis undergoing treatment with antifungal antibiotics Magn Reson Imaging 14 1996 615 658
34. A. Shirkhoda, G. Lopez-Berestein, M.J. Holbert, and M.A. Luna Hepatosplenic fungal infection CT and pathologic evolution after treatment with liposomal amphotericin B Radiology 159 1986 349 353
35. R.C. Semelka, N.L. Kelekis, S. Sallah, S. Worawattanakul, and S.M. Archer Hepatosplenic fungal disease, diagnostic accuracy and spectrum of appearances on MR imaging Am J Roentgenol 169 1997 1311 1316
36. V.J. Anttila, A.E. Lamminen, S. Bondestam, A. Korhola, M. Farkkila, and A. Sivonen Magnetic Resonance imaging is superior to computed tomography and ultrasonography in imaging infectious liver foci in acute leukemia Eur J Haematol 56 1998 82 87
37. B.C. Pestalozzi, G.P. Krestin, U. Schanz, E. Jacky, and J. Gmur Hepatic lesions of chronic disseminated candidiasis may become invisible during neutropenia Blood 90 1997 3858 3864
38. T.J. Walsh, W.G. Merz, J.W. Lee, R. Schaufele, T. Sein, and P.O. Whitcomb Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum d-arabinitol Am J Med 99 1995 164 172
39. G. Morace, L. Pagano, M. Sanguinetti, B. Posteraro, L. Mele, and F. Equitani PCR restriction enzyme analysis for detection of Candida DNA in blood from febrile patients with hemotological malignancies J Clin Microbiol 37 1999 1871 1875
40. H. Einsele, H. Hebart, G. Roller, J. Loffler, I. Rothenhofer, and C.A. Muller Detection and identification of fungal pathogens in blood by using molecular probes J Clin Microbiol 35 1997 1353 1360
41. S. de Marie New developments in the diagnosis and management of invasive fungal infections Haematologica 85 2000 88 93
42. M.J. Zervos, and J.A. Vazques DNA analysis in the study of fungal infections m the immunocompromised host Clin Lab Med 16 1996 73 88
43. T.J. Walsh, P.O. Whitcomb, S.G. Revankar, and P.A. Pizzo Successful treatment of hepatosplenic candidiasis through repeated cycles of chemotherapy and neutropenia Cancer 76 1995 2357 2362
44. A. Loeliger, M. van Leeuwen, M. Rozenberg-Arsa, and A.W. Dekker Hepatosplenic candidiasis, a fatal disease? Infection 20 1992 336 338
45. H.A. Gallis, R.H. Drew, and W.W. Pickard Amphotericin B, 30 years of clinical experience Rev Infect Dis 12 1990 308 329
46. J.E. Edwards, G.P. Bodey, R.A. Bowden, T. Buchner, B.E. de Pauw, and S.G. Filler International conference for the development of consensus on the management and prevention of severe candidal infections Clin Infect Dis 25 1997 43 59
47. J. Brajtburg, W.G. Powderly, G.S. Kobayashi, and G. Medoff Amphotericin B, current understanding of mechanism of action Antimicrob Agents Chemother 34 1990 183 188
48. K. Katayama, S. Koizumi, M. Yamagami, Y. Tamaru, T. Ichihara, and M. Konishi Successful peritransplant therapy in children with acute hepatosplenic candidiasis Int J Haematol 59 1994 125 130
49. R. Sabra, and R.A. Branch Amphotericin B nephrotoxicity Drug Safety 5 1990 94 108
50. D.W. Wamock Amphotericin B, an introduction J Antimicrob Chemother 28 1991 227 238
51. C.A. Kauffman, S.F. Bradley, S.C. Ross, and D.R. Weber Hepatosplenic candidiasis, successful treatment with fluconazole Am J Med 91 1991 137 141
52. E. Anaissie, G.P. Bodey, H. Kantarjian, C. David, K. Barnett, and E. Bow Fluconazole therapy for chronic disseminated candidiasis in patients with leukemia and prior amphotericin B therapy Am J Med 91 1991 142 149
53. R. Patel Antifungal agents, amphotericin B preparations and flucytosine Mayo Clin Proc 73 1998 1205 1225
54. A.S. Janoff, L.T. Boni, M.C. Popescu, S.R. Minchey, P.R. Cullis, and T.D. Madden Unusual lipid structures selectively reduce the toxicity of amphotericin B Proc Natl Acad Sci USA 85 1988 6122 6126
55. M.J. Ostro, and P.R. Cullis Use of liposomes as injectable-drug delivery systems Am J Hosp Pharm 46 1989 1576 1587
56. R.M. Fielding Liposomal drug delivery, advantages and limitations from a clinical pharmacokinetic and therapeutic perspective Clin Pharmacokinet 21 1991 155 164
57. V.L. Kan, J.E. Bennett, M.A. Amantea, M.C. Smolskis, E. McManus, and D.M. Grasela Comparative safety, tolerance, and pharmacokinetics of amphotericin B lipid complex and amphotericin B deoxycholate in healthy male volunteers J Infect Dis 164 1991 418 421
58. W.R. Perkins, S.R. Minchey, L.T. Boni, C.E. Swenson, M.C. Popescu, and R.F. Pasternack Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity Biochem Biophys Acta 1107 1992 271 282
59. J.M. Clark, R.R. Whitney, S.J. Olsen, R.J. George, M.R. Swerdel, and L. Kunselman Amphotericin B lipid complex therapy of experimental fungal infections in mice Antimicrob Agents Chemother 35 1991 615 621
60. S.J. Olsen, M.R. Swerdel, B. Blue, J.M. Clark, and D.P. Bonner Tissue distribution of amphotericin B lipid complex in laboratory animals J Pharm Pharmacol 43 1991 831 835
61. T.J. Walsh, R.W. Finberg, C. Amdt, J. Hiemenz, C. Schwartz, and D. Bodensteiner Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia N Engl J Med 340 1999 764 771
62. G. Lopez-Berestein, R.L. Hopfer, R. Metha, K. Metha, E.M. Hersh, and R.L. Juliano Liposome-encapsulated amphotericin B for treatment disseminated candidiasis in neutropenic mice J Infect Dis 150 1984 278 283
63. G. Lopez-Berestein, G.P. Bodey, L.S. Frankel, and K. Metha Treatment of hepatosplenic candidiasis with liposomal-amphotericin B J Clin Oncol 5 1987 310 317
64. T.J. Walsh, J.W. Hiemenz, N.L. Seibel, J.R. Perfect, G. Horwith, and L. Lee Amphotericin B lipid complex for invasive fungal infections, analysis of safety and efficacy in 556 cases Clin Infect Dis 26 1998 1383 1396
65. A. Won-Beringer, R.A. Jacobs, and B.J. Guglielemo Lipid amphotericin B clinical efficacy and toxicities Clin Infect Dis 27 1998 603 618
66. J.W. Heimenz, and T.J. Walsh Lipid formulations of amphotericin B, recent progress and future directions Clin Infect Dis 22 1996 S113 S134
67. T.J. Walsh, P. Whitcomb, S. Piscitelli, W.D. Figg, S. Hill, and S.J. Chanock Safety tolerance and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis Antimicrob Agents Chemother 41 1997 1944 1948
68. S. Kline, T.A. Larsen, L. Fieber, R. Fishback, M. Greenwood, and R. Harris Limited toxicity of prolonged therapy with high doses of amphotericin B lipid complex Clin Infect Dis 21 1995 1154 1158
69. S. Sallah, R.C. Semelka, W. Sallah, J.R. Vainright, and D.L. Philips Amphotericin B lipid complex for the treatment of patients with acute leukemia and hepatosplenic candidiasis Leuk Res 23 1999 995 999
70. A. Polak Combination therapy with antifungal drugs Mycoses 31 1988 45 53
71. J.E. Bennett Flucytosine Ann Intern Med 86 1977 319 322
72. R.B. Diasio, D.E. Lakings, and J.E. Bennett Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans, possible factor in 5-fluorocytosine clinical toxicity Antimicrob Agents Chemother 14 1978 903 908
73. A.M. Stamm, R.B. Diasio, W.E. Dismukes, S. Shadom, G.A. Cloud, and C.A. Bowles Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis Am J Med 83 1987 236 242
74. P. Francis, and T.J. Walsh Evolving role of fluorocytosine in immunocompromised patients, new insights into safety, pharmacokinetics and antifungal therapy Clin Infect Dis 15 1992 1003 1018
75. A.M. Sugar Use of amphotericin B with azole antifungal drugs, what are we doing Antimicrob Agents Chemother 39 1995 1907 1912
76. E. Martin, F. Maier, and S. Bhakdi Antagonistic effects of fluconazole and 5-fluorocytosine on candidacidal action of amphotericin B in human serum Antimicrob Agents Chemother 38 1994 1331 1338
77. M. Scheven, and L. Senf Quantitative determination of fluconazole-amphotericin B antagonism to Candida albicans by agar diffusion Mycoses 37 1994 205 207
78. M. Thaler, J. Bacher, T. O'Leary, and P.A. Pizzo Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia J Infect Dis 158 1988 80 88
79. A.M. Sugar, C.A. Hitchcock, P.F. Troke, and M. Picard Combination therapy for murine invasive candidiasis with fluconazole and amphotericin B Antimicrob Agents Chemother 39 1995 598 601
80. American Society of Clinical Oncology American Society of Clinical Oncology recommendations for the use of hematopoietic colony stimulating factors, evidence-based, clinical practice guidelines J Clin Oncol 12 1994 2471 2508
81. R. Pettengell, H. Gurney, J.A. Radford, D.P. Deakin, R. James, and P.M. Wilkinson Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma, a randomized controlled trial Blood 80 1992 1430 1436
82. A. Freifeld, and P. Pizzo Colony-stimulating factors and neutropenia, intersection of data and clinical relevance J Natl Cancer Inst 87 1995 781 782
83. G.P. Bodey, E. Anaissie, J. Gutterman, and S. Vadhan-Raj Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer Clin Infect Dis 17 1993 705 707
84. L.A. Bober, M.H. Grace, C. Pugliese-Sivo, A. Rojas-Triana, T. Waters, and L.M. Sullivan The effect of GM-CSF and G-CSF on human neutrophil function Immunopharmacology 29 1995 111 119
85. A. Vecchiarelli, C. Monari, F. Baldelli, D. Pietrella, C. Retini, and C. Tascini Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphnuclear leukocytes from patients with AIDS J Infect Dis 171 1995 448 454
86. J.L. Goodman, D.J. Winston, R.A. Greenfield, P.H. Chandrasekar, B. Fox, and H. Kaizer A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation N Engl J Med 326 1992 845 851
87. D.J. Winston, P.H. Chandrasekar, H.M. Lazarus, J.L. Goodman, J.L. Silber, and H. Horowitz Fluconazole prophylaxis of fungal infections in patients with acute leukemia, results of a randomized placebo-controlled, double-blind, multicenter trial Ann Intern Med 118 1993 495 503
88. D.K. Riley, A.T. Pavia, P.G. Beatty, F.B. Petersen, J.L. Spruance, and R. Stokes The prophylactic use of low-dose amphotericin B in bone marrow transplant patients Am J Med 97 1994 509 514
89. J.R. Perfect, M.E. Klotman, C.C. Gilbert, D.D. Crawford, G.L. Rosner, and K.A. Wright Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients J Infect Dis 165 1992 891 897
90. J.R. Wingard, W.G. Merz, M.G. Rinaldi, T.R. Johnson, J.E. Karp, and R. Saral Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole N Engl J Med 325 1991 1274 1277
91. M.H. Nguyen, J.E. Peacock Jr., A.J. Morris, D.C. Tanner, M.L. Nguyen, and D.R. Snydman The changing face of candidemia, emergence of non-Candida albicans species and antifungal resistance Am J Med 100 1996 617 623
92. W.T. Hughes, D. Armstrong, G.P. Bodey, A.E. Brown, J.E. Edwards, and R. Feld 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever Clin Infect Dis 25 1997 551 573
93. T.J. Walsh, P. Pappas, D.J. Winston, H.M. Lazarus, F. Petersen, and J. Raffalli Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 2002 225 234
94. J. Mora-Duarte, R. Betts, C. Rotstein, A.L. Colombo, L. Thompson-Moya, and J. Smietana Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
95. F. Sora, P. Chiusolo, N. Piccirillo, L. Pagano, L. Laurenti, and G. Farina Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B Clin Infect Dis 35 2002 1135 1136
96. E.H. Choi, C.B. Foster, J.G. Taylor, H.C. Erichsen, R.A. Chen, and T.J. Walsh Association between chronic disseminated candidiasis in adult acute leukemia and common IL-4 promoter haplotypes J Infect Dis 187 2003 1153 1156
97. L. Romani Immunity to Candida albicans Th1, Th2 cells and beyond Curr Opin Microbiol 2 1999 363 367
98. L. Romani, P. Puccetti, A. Mencacci, E. Cenci, R. Spaccapelo, and L. Tonnelti Neutralization of IL-10 upregulates nitric oxide production and protects susceptible mice from challenge with Candida albicans J Immunol 152 1994 3514 3521